Protagonist Therapeutics (PTGX) Long-Term Deferred Tax (2018 - 2020)

Protagonist Therapeutics has reported Long-Term Deferred Tax for 3 years, with the latest figure at $1.1 million in Q1 2020.

• Quarterly Long-Term Deferred Tax rose 126.36% year-over-year to $1.1 million in Q1 2020, while the trailing twelve-month figure through Mar 2020 was $1.1 million (up 126.36% YoY) and the FY2019 annual result came in at $1.4 million, up 117.78% from the prior year.
• Long-Term Deferred Tax retreated to $1.1 million in Q1 2020 per PTGX's latest filing, from $1.4 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $2.1 million in Q3 2019 and troughed at $478000.0 in Q1 2019.
• A 3-year average of $1.3 million and a median of $1.3 million in 2019 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2019 and 2020: Long-Term Deferred Tax surged 117.78% in 2019, then soared 126.36% in 2020.
• Over 3 years, Long-Term Deferred Tax stood at $658000.0 in 2018, then soared by 117.78% to $1.4 million in 2019, then dropped by 24.49% to $1.1 million in 2020.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $1.1 million, $1.4 million, and $2.1 million for Q1 2020, Q4 2019, and Q3 2019 respectively.